Molecular signatures in the diagnosis and management of follicular lymphoma

Current Opinion in Hematology

Volumn 17, Issue 4, 2010, Pages 333-340

  Wrench, David ^a   Montoto, Silvia ^a   Fitzgibbon, Jude ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

epigenetics; follicular lymphoma; mutation; predisposition; progenitor; transformation

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PESTICIDE;

CHROMOSOME 6P; EPIGENETICS; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEM CELL; TREATMENT OUTCOME; CHROMOSOME 14; CHROMOSOME 18; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; LYMPHOMA, FOLLICULAR; MUTATION;

CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, FOLLICULAR; MUTATION; TRANSLOCATION, GENETIC;

EID: 77954073547     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328338ccab     Document Type: Review

References (85)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-2795.
2. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-147.
3. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24:1582-1589.
4. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23:5019-5026.
5. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447-8452.
6. Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009:532-541.
7. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-1265.
8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27:4555-4562.
9. Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoetic and lymphoid tissues, 4th ed. Lyon, France: IARC; 2008. pp. 220-226.
10. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317:1185-1189.
11. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85:2528-2536.
12. Schuler F, Dolken L, Hirt C, et al. Prevalence and frequency of circulating t(14;1 8)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009; 124:958-963.
13. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265-276.
14. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27:1202-1208.
15. Agopian J, Navarro JM, Gac AC, et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 2009;206:1473-1483.
16. Marco F, Manjon R, Richard C, et al. Simultaneous occurrence of follicular lymphoma in two monozygotic twins. Br J Haematol 1999; 107:461-462.
17. Last KW, Goff LK, Summers KE, et al. Familial follicular lymphoma: a case report with molecular analysis. Br J Haematol 2000; 110:744-745.
18. Skibola CF, Bracci PM, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet 2009; 41:873-875.
19. Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 3161-3169.
20. Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009; 18:1259-1270.
21. Novak AJ, Slager SL, Fredericksen ZS, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009; 69:4217-4224.
22. Skibola CF, Nieters A, Bracci PM, et al. Afunctional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 2008; 111:4348-4354.
23. Wang SS, Maurer MJ, Morton LM, et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009; 23:596-602.
24. Han X, Zheng T, Foss FM, et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010; 85:51-56.
25. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109:5439-5446.
26. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One 2008; 3:e2816.
27. Goldin LR, Bjorkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91-94.
28. d'Amore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;1 8)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res 2008; 14:7180-7187.
29. Johnson NA, Al-Tourah A, Brown CJ, et al. Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes Cancer 2008; 47:1038-1048.
30. Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30:375-382.
31. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23:6358-6363.
32. Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predo minantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009; 113:1053-1061.
33. Christie L, Kernohan N, Levison D, et al. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator? Leuk Lymphoma 2008; 49:470-476.
34. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;1 8) and 8q24/c-MYC rearrangement. Haematologica 2007; 92:1335-1342.
35. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273-2279.
36. Quijano S, Lopez A, Rasillo A, et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood 2008; 111:5130-5141.
37. Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009; 113:137-148.
38. Fitzgibbon J, Iqbal S, Davies A, etal. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia 2007; 21:1514-1520.
39. O'Shea D, O'Riain C, Gupta M, etal. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009; 113:2298-2301.
40. Ross CW, Ouillette PD, Saddler CM, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007; 13:4777-4785.
41. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leuke-mias. Cancer Res 2005; 65:9152-9154.
42. Mardis ER, Ding L, Dooling DJ, etal. Recurring mutations found by sequen-cing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
43. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456:66-72.
44. Morin RD, Johnson NA, Severson TM, etal. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-185.
45. Cheung KJ, Johnson N, Affleck J, et al. TNFRSF14 is mutated in a subset of follicular lymphoma and correlated with inferior prognosis [abstract #1919]. Blood 2009; 114:761.
46. O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008; 112:3126-3129.
47. Johnson NA, Morin R, Severson T, etal. FAS mutations in follicular lymphoma are rare but associated with aggressive clinical behavior [abstract #3967]. Blood 2009; 114:1525.
48. Van Haaften G, Dalgliesh GL, Davies H, etal. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41:521-523.
49. Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006; 5:44.
50. Killian JK, Bilke S, Davis S, etal. Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. Cancer Res 2009; 69:758-764.
51. Martin-Subero JI, Ammerpohl O, Bibikova M, et al. A comprehensive micro-array-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009; 4:e6986.
52. Martin-Subero JI, Kreuz M, Bibikova M, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigeno-mic, genomic, and transcriptional profiling. Blood 2009; 113:2488-2497.
53. Bennett LB, Schnabel JL, Kelchen JM, et al. DNA hypermethylation accom-panied by transcriptional repression in follicular lymphoma. Genes Chromo somes Cancer 2009; 48:828-841.
54. O'Riain C, O'Shea DM, Yang Y, et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia 2009; 23:1858-1866.
55. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647:21-29.
56. Carlotti E, Wrench D, Matthews J, etal. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 2009; 113:3553-3557.
57. Gentles AJ, Alizadeh AA, Lee SI, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma pa tients. Blood 2009; 114:3158-3166.
58. Ruminy P, Jardin F, Picquenot JM, et al. S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. Blood 2008; 112:1951-1959.
59. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165-5169.
60. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426-2433.
61. Gine E, Montoto S, Bosch F, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006; 17:1539-1545.
62. Hart J, Turner AR, Larratt L, et al. Transmission of a follicular lymphoma by allogeneic bone marrow transplantation: evidence to support the existence of lymphoma progenitor cells. Br J Haematol 2007; 136:166-167.
63. Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101:3109-3117.
64. Lossos IS, Alizadeh AA, Diehn M, etal. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99:8886-8891.
65. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohisto-chemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25:390-398.
66. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136:286-293.
67. Matolcsy A, Schattner EJ, Knowles DM, Casali P. Clonal evolution of B cells in transformation from low-to high-grade lymphoma. Eur J Immunol 1999; 29:1253-1264.
68. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-2169.
69. Burger JA, GhiaP, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114:3367-3375.
70. Gupta M, Dillon SR, Ziesmer SC, et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapa-mycin activation. Blood 2009; 113:5206-5216.
71. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99:282-289.
72. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic altera tions. Blood 2009; 114:826-834.
73. Piccaluga PP, Califano A, Klein U, et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 2008; 93:1033-1038.
74. Glas AM, Kersten MJ, Delahaye LJ, etal. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105:301-307.
75. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003; 100:1926-1930.
76. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142:732-744.
77. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009; 13:1248-1260.
78. He L, Thomson JM, Hemann MT, etal. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828-833.
79. Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109:3922-3928.
80. Byers RJ, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008; 111:4764-4770.
81. Jack A. Organisation of neoplastic haematopathology services: a UK perspective. Pathology 2005; 37:479-492.
82. Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2010; 28:822-829.
83. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111:4004-4013.
84. Montoto S, Moreno C, Domingo-Domenech E, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxan-trone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 2008; 93:207-214.
85. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009; 27:6094-6100.